DE PAOLI, LORENZO
 Distribuzione geografica
Continente #
EU - Europa 368
NA - Nord America 253
AS - Asia 75
Totale 696
Nazione #
US - Stati Uniti d'America 250
IE - Irlanda 133
SE - Svezia 71
DE - Germania 67
IT - Italia 53
UA - Ucraina 27
HK - Hong Kong 22
IN - India 18
CN - Cina 16
SG - Singapore 12
FI - Finlandia 7
IR - Iran 7
CA - Canada 3
CZ - Repubblica Ceca 3
AL - Albania 2
NL - Olanda 2
CH - Svizzera 1
FR - Francia 1
GB - Regno Unito 1
Totale 696
Città #
Dublin 133
Jacksonville 49
Chandler 37
Hong Kong 22
Piemonte 19
Dearborn 18
Bremen 15
Lawrence 15
Princeton 15
Grafing 13
Boardman 12
Wilmington 12
Beijing 7
Munich 6
Singapore 6
Cassano Magnago 4
San Mateo 4
Turin 4
Ashburn 3
Brno 3
Helsinki 3
Houston 3
Novara 3
Woodbridge 3
Zanjan 3
Ann Arbor 2
Berlin 2
Castellazzo Bormida 2
Guangzhou 2
Hefei 2
Nanjing 2
Parma 2
Tirana 2
West Jordan 2
Altavilla Monferrato 1
Andover 1
Arona 1
Biella 1
Düsseldorf 1
Fairfield 1
Guiyang 1
Leawood 1
Milan 1
Montréal 1
Mumbai 1
Nanchang 1
Naples 1
Seattle 1
Strasbourg 1
Toronto 1
Trani 1
Vercelli 1
Villavesco 1
Voghera 1
Winnipeg 1
Zhengzhou 1
Zurich 1
Totale 453
Nome #
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. 86
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 68
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia 64
Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication 60
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 59
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 56
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 50
RICHTER SYNDROME: FROM MOLECULAR GENETIC TO THERAPEUTIC STRATEGIES 50
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 49
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma 40
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy 38
Radiotherapy in COVID-19 patient affected by multiple myeloma: A case report 33
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 26
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 25
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 23
Totale 727
Categoria #
all - tutte 4.183
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.183


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202096 0 0 7 0 9 12 18 5 8 28 9 0
2020/202167 8 2 9 0 10 4 9 0 12 2 11 0
2021/2022101 1 2 2 14 4 0 15 2 4 11 21 25
2022/2023299 17 15 29 5 21 26 7 21 142 1 9 6
2023/202494 10 8 8 2 11 2 21 1 0 5 3 23
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 727